Juan R. Berenguer
Distinguished in Hepatitis

Juan R. Berenguer

Madrid, MD, ES 
Distinguished in Hepatitis
Madrid, MD, ES 
OverviewLocationsClinical Research

Overview

Juan Berenguer practices in Madrid, Spain. Mr. Berenguer is rated as a Distinguished expert by MediFind in the treatment of Hepatitis. His top areas of expertise are Hepatitis C, Hepatitis, HIV/AIDS, and Cirrhosis.

His clinical research consists of co-authoring 223 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 120 articles and participated in 1 clinical trial in the study of Hepatitis.

Gender
Male

Locations

Madrid, MD, Spain
Other Locations
Majadahonda, MD, Spain
La Paz, MD, Spain
Cordoba, AN, Spain
Maranon, NC, Spain
Barcelona, CT, Spain
Malaga, AN, Spain
Logrono, LO 26006, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase IIb, Randomized, Double-blind, Parallel-group Study to Assess the Efficacy, Safety, Tolerability, and Resistance Profile of GSK3640254 in Combination With Dolutegravir Compared to Dolutegravir Plus Lamivudine in HIV-1 Infected, Treatment-naïve Adults
A Phase IIb, Randomized, Double-blind, Parallel-group Study to Assess the Efficacy, Safety, Tolerability, and Resistance Profile of GSK3640254 in Combination With Dolutegravir Compared to Dolutegravir Plus Lamivudine in HIV-1 Infected, Treatment-naïve Adults
Enrollment Status: Terminated
Publish Date: December 14, 2023
Intervention Type: Drug
Study Drugs: GSK3640254, Dolutegravir, Lamivudine
Study Phase: Phase 2
A Phase III, Open Label, Multicentric Clinical Trial of a Single Arm of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotype 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A
A Phase III, Open Label, Multicentric Clinical Trial of a Single Arm of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotype 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A
Enrollment Status: Withdrawn
Publish Date: June 08, 2018
Intervention Type: Drug
Study Phase: Phase 4
View 1 Less Clinical Trial

221 Total Publications

Effectiveness and Safety of COVID-19 mRNA Vaccines in Children 6-17 Years Old: A Population-Based Study in Madrid.
Effectiveness and Safety of COVID-19 mRNA Vaccines in Children 6-17 Years Old: A Population-Based Study in Madrid.
Journal: The Pediatric infectious disease journal
Published: December 16, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Berenguer's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile